Brisbane Times
·general
·2 hours ago
Why ‘Big Pharma’ isn’t cashing in on the peptide craze
Big pharmaceutical companies are hesitant to develop popular unregulated peptides in Australia, believing they lack safety and profitability. Ana Svensson from Novo Nordisk emphasized that these substances have not undergone rigorous evaluations and do not meet safety standards. The lengthy drug approval process further deters investment in these experimental products.
Summary by Glance · Brisbane Times
Newer
Next
Loving doing this? 🎉
Take it further — get the full app and never miss a moment of what's happening in Australia.
Breaking news alerts
Instant lock-screen notifications the moment big stories break across Australia.
Australian news & events
Politics, sport, weather, local events — all in one swipeable feed, updated around the clock.
Stay ahead of the news cycle
30-second summaries so you're always informed, even on your busiest days.
Loading article…
This publisher's site can't be shown here due to their security settings.
Open full article →No source link available for this article.
✨
Ask AI